The funds will help the company prepare for CLIA certification of its lab ahead of the planned launch of its lung cancer test.
Certain investors have agreed to buy 375,000 shares of Interpaces common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share.
The Rutherford, NJ-based cancer molecular diagnostics firm will use the proceeds for general corporate purposes.
The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.
The molecular diagnostics firm has retained Roth Capital Partners as financial advisor to assist in restructuring Series C Warrants issued in March.
The firm closed its existing debt facility with Silicon Valley Bank and Oxford Finance and plans to use the funds for general corporate purposes and working capital.
The offering raised net proceeds of $6.2 million, which will be used for working capital and general corporate purposes, the firm said.
The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit.
CombiMatrix expects to receive net proceeds of $4.75 million from the offering, which it plans to use for general corporate purposes.
The firm said in an SEC document that it plans to offer up to $11.5 million in its common shares and up to $11.5 million in common stock issuable upon the exercise of warrants.
The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.
The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.
Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.
In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.